The IPCR calls on the strength of more than 40 scientists and scientist-clinicians in multiple disciplines. Many are international leaders in their fields.
Together these researchers have already identified and/or assembled up to 80 percent of the genes expressed in prostate cancer, developed one of the largest serum and tissue banks in the world, undertaken some of the most advanced studies of bone biology and skeletal metastases, assembled information and genotypes for more than 300 families with hereditary prostate cancer, and developed many new therapeutic strategies.
Since the IPCR’s formation, its faculty members have been awarded more than $40 million in research grants from the National Institutes of Health and other federal agencies. This includes one of only 10 prostate cancer Specialized Program of Research Excellence (SPORE) grants nationwide from the National Cancer Institute to study prostate cancer progression.
IPCR faculty members also have received many other individual grants to study numerous aspects of prostate cancer. Receiving this level of private and federal funding constitutes a tremendous accomplishment and demonstrates the excellence of our faculty members and their work.
Together, these scientists and clinicians provide hope for men with prostate cancer and their families in the Northwest and the world.